Company
Headquarters: Vancouver, BC, Canada
Employees: 3
CEO: Mr. John Davies
| Company | Market Cap (USD) | 
|---|---|
| Novo Nordisk | $309.91 B | 
| Vertex Pharmaceuticals Incorporated | $117.36 B | 
| CSL Limited | $95.75 B | 
| Regeneron Pharmaceuticals, Inc. | $59.14 B | 
| Marinomed Biotech AG | $58.56 B | 
| Company | Market Cap (USD) | 
|---|---|
| Lilly | $699.59 B | 
| Johnson & Johnson | $374.29 B | 
| AbbVie | $336.94 B | 
| Novo Nordisk | $309.91 B | 
| UnitedHealth Group | $279.90 B | 
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Gemina Laboratories Ltd has the following listings and related stock indices.
Stock: CSE: GLAB wb_incandescent